Xebra Brands Ltd.

OTC: XBRAF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCReports USD

#1039 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

——

FH —DQ —GM —SS 7

v0.1 · 5/100 weight · pillars only

↑ disclosure history, revenue growth (YoY) · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$1.4M

Employees

Market cap

$1.5k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$79.1k106.9k CAD2024

Net income-$1.4M-2.0M CAD2024

Operating income-$1.2M-1.6M CAD2024

Total assets$279.5k379.4k CAD2024

Liabilities$582.0k790.0k CAD2024

Equity-$113.8k-154.5k CAD2024

Revenue trend

FY2020 – FY2024 · USD

FY20

FY21

FY22

$121.0k

FY23

$79.1k

FY24

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Xebra Brands Ltd. booked $79.1k in FY2024 revenue, contracting 35% year over year — slower than 78% of Healthcare companies we track, at a -1831.8% net margin.

Peers · Healthcare

Xcorporeal, Inc.——Peoplesway.com Inc.——RBC Life Sciences, Inc.——Assure Holdings Corp.——

Key facts

CEORodrigo Valencia Gallardo

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: XBRAF

Employees2

IPO date2021-11-24

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.